Mesoblast (ASX: $MSB) report quarterly revenues from sales  in Japan up 99% pcp to US$2.1 million. On a rolling 12-month basis, revenues were US$7.6 million, an increase of 75% pcp. https://t.co/vEM6Ol7HXg. #medicines #inflammation #ASX #stocks. https://t.co/2iSA63TCNy